drugset / Trial / NCT04649983
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2023-12-31
- Completion
- 2024-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 and CD22 targeted CAR-T cells | Cell therapy | — | Intravenous |